Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial.
Shahid Ahmed(Emory University), Mike Moser(Roswell Park Comprehensive Cancer Center), Duc Le(University of Saskatchewan), Austin Hammond(University of Saskatchewan), Haji Chalchal, Deborah H. Anderson(University of Saskatchewan), Rajan Rakheja(University of Saskatchewan), Lynn Dwernychuk(Saskatchewan Cancer Agency), Franco J. Vizeacoumar(Royal University Hospital), Rani Kanthan(University of Saskatchewan), Adnan Zaidi(University of Saskatchewan), June Lim(University of Saskatchewan), Josh Gitlin(University of Saskatchewan), Dilip Gill(University of Saskatchewan), Nazmi Sari(University of Saskatchewan)
Cited by 2
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301
The Genotype-Tissue Expression (GTEx) project
|Nature Genetics|2013|266
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
|Journal of Clinical Oncology|2013|261